Avalanche Biotechnologies reports weak data

A small study of Avalanche Biotechnologies Inc.'s (Nasdaq: AAVL) age-related chronic eye disease treatment AVA-101 achieved its safety goal but demonstrated only modest vision improvement sending the stock price plummeting $21.38 to $17.50.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.